dr. xia on the frontline treatment landscape of alk-positive nsclc
Published 5 years ago • 242 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
1:22
dr. liu on navigating the frontline treatment of alk nsclc
-
6:51
progression in alk nsclc after frontline therapy
-
2:21
current treatment landscape for alk-positive nsclc
-
1:52
dr. drilon on the utility of brigatinib in alk nsclc
-
8:24
second-line treatment for alk-positive nsclc
-
1:42
dr. velcheti on potential of alectinib in frontline alk-positive nsclc
-
8:24
second-line treatment for alk-positive nsclc
-
4:33
shaw the changing landscape of first-line treatment of alk-pos advanced nsclc
-
13:28
debate: alk positive nsclc - front line therapy - crizotinib
-
6:22
targeted tkis used for treatment of alk-positive nsclc
-
1:57
dr. shaw on sequencing strategies in alk-positive nsclc
-
8:15
alex trial: frontline therapy for alk-rearranged nsclc
-
11:38
debate: alk positive nsclc - front line therapy - ceritinib
-
1:30
dr. kelly on the outlook of alk-positive nsclc
-
1:39
dr. leach on brigatinib in alk-positive nsclc
-
4:31
alk-positive nsclc: alex trial
-
3:34
alk-positive nsclc: the role of treatment selection and sequencing
-
1:27
dr. ou on the use of crizotinib in patients with ros1-rearranged nsclc
-
1:11
dr. salgia on crizotinib and other tkis in alk-positive nsclc